Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.53 |
| ▸ | VEGFA | P15692 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072566 | 0.82 | THRA (0.64) | EGLN1FTOBBOX1 | |
| SCHEMBL5070927 | 0.81 | EGLN1 (0.49) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL521828 | 0.80 | EGLN1 (0.56) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL821293 | 0.77 | EGLN1 (0.68) | EGLN1EGLN3FTOKDM6BBBOX1 | |
| SCHEMBL31501044 | 0.77 | EGLN1 (0.68) | EGLN1EGLN3FTOKDM6BBBOX1 | |
| SCHEMBL9893450 | 0.75 | EGLN1 (0.48) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL1921903 | 0.75 | EGLN1 (0.67) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL6061077 | 0.74 | KDM4E (0.43) | — | |
| SCHEMBL14310480 | 0.73 | EGLN1 (0.71) | EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL523283 | 0.71 | EGLN1 (0.51) | EGLN1EGLN3VEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| EP-2035000-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146438-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007047194-A2 | METHODS FOR TREATING MITF-RELATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |